Organogenesis Holdings Inc.

NASDAQ:ORGO

Drug Manufacturers - Specialty & Generic

Healthcare
$0.85 +3.21%

+$0.08 today

Market cap
$110.75M
Beta
1.33
P/E (TTM)
-1086.7
EPS (TTM)
-$0.00
52W Low $2.04High $7.08

Volume 0.86M

Average 1.49M

ORGO Income Before Tax

Profit after all operating and non-operating items but before income tax.

Organogenesis Holdings Inc.NASDAQ: ORGO

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$68.47M, compared with -$25.78M a year earlier. Trailing-twelve-month income before tax was $4.28M. Over 3 fiscal years it compounded at +32.3% a year.

Context

  • Income before tax amounted to 8.3% of revenue in FY2025, up 7.8 pp from a year earlier.
  • Income before tax increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$68.47M or moves back toward the trailing-twelve-month quarterly average of $1.07M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$68.47M-208.0% QoQ
Last fiscal yearDec 2025
$46.97M+1773.3% YoY
LTMMar 2026
$4.28M+117.7% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-165.6%——
1 year+1773.3%——
3-year CAGR+32.3%——
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
46.97M USD
Year-over-year change
+1773.3%
4-year CAGR
-7.1%

Income Before Tax vs competitors

How ORGO compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +117.7% is the highest of 11, against a peer median of +16.4%.
  • Income before tax amounts to 0.8% of revenue for ORGO, versus a peer median of 9.4%.
ORGO Competitors
Income Before Tax for ORGO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SIGASIGA Technologies, Inc.LTM Mar 2026$26.93M USD-56.8%-11.7%28.7%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$4.28M USD+117.7%+32.3%0.8%
EBSEmergent BioSolutions Inc.LTM Mar 2026$3.5M USD+105.6%—0.5%
ESPREsperion Therapeutics, Inc.LTM Mar 2026-$5.58M USD+96.4%—1.3%
SNDLSNDL Inc.LTM Mar 2026-CA$12.48M CAD+88.9%—1.3%
MNPRMonopar Therapeutics Inc.LTM Mar 2026-$14.98M USD+9.6%——
ANGOAngioDynamics, Inc.LTM Feb 2026-$31.38M USD+25.4%—10.0%
EOLSEvolus, Inc.LTM Mar 2026-$42.56M USD+23.3%—14.1%
CMPXCompass Therapeutics, Inc.LTM Mar 2026-$68.17M USD-23.5%——
VREXVarex Imaging CorporationLTM Apr 2026-$75.1M USD-552.4%—8.8%
BCYCBicycle Therapeutics plcLTM Mar 2026-$217.62M USD-4.3%—342.7%
Peer median (excluding ORGO) —+16.4%-11.7%9.4%

Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue467.36M450.89M433.14M482.04M563.03M
Cost of Revenue114.2M105.02M106.48M115.74M137.52M
Gross Profit353.16M345.87M326.66M366.3M425.51M
Gross Margin75.6%76.7%75.4%76.0%75.6%
Research & Development30.74M39.76M44.38M50.27M44.54M
Selling, General & Admin250.2M283.81M269.75M294.51M326.24M
Operating Expenses280.94M323.57M314.13M367.59M369.64M
Depreciation & Amortization16.68M18.03M23.45M17.03M26.94M
EBITDA87M40.32M36.03M15.76M73.91M
EBITDA Margin18.6%8.9%8.3%3.3%13.1%
Operating Income72.22M22.3M12.53M(1.28M)55.87M
Operating Margin15.5%4.9%2.9%-0.3%9.9%
Interest Income00002.28M
Interest Expense7.24M2.01M2.19M1.54M0
Other Income / Expenses(9.13M)(2.02M)(2.13M)(1.52M)(8.9M)
Income Before Tax63.09M20.28M10.39M(2.81M)46.97M
Pre-Tax Margin13.5%4.5%2.4%-0.6%8.3%
Income Tax Expense(31.12M)4.75M5.45M(3.67M)9.94M
Net Income94.2M15.53M4.95M861K37.03M
Net Margin20.2%3.4%1.1%0.2%6.6%
EPS (Basic)0.730.120.04(0.01)0.16
EPS (Diluted)0.700.120.04(0.01)0.15
Weighted Avg Shares128.33M130.07M131.23M131.67M126.74M
Weighted Avg Shares (Diluted)133.66M132.38M132.75M131.67M130.25M

Organogenesis Holdings Inc.

NASDAQ:ORGO

Intrinsic Alpha fair value

Locked

Current Price

$0.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.